Risk Of Developing Liver Cancer After HCV Treatment

▼
Showing posts with label BI 207127. Show all posts
Showing posts with label BI 207127. Show all posts
Wednesday, January 29, 2014

Boehringer Ingelheim halts further development of deleobuvir-containing hepatitis C regimens

›
Boehringer Ingelheim halts further development of deleobuvir-containing hepatitis C regimens January 17, 2014 Reprinted from company state...
Wednesday, September 19, 2012

BI exits virology research as hep C drugs move down pipeline

›
BI exits virology research as hep C drugs move down pipeline Kevin Grogan Boehringer spokeswoman Julia Meyer-Kleinmann told PharmaTim...
Monday, November 7, 2011

AASLD-BI 201335 plus BI 207127 and ribavirin-76% virological response at week 12, and 59% achieve SVR12 with 16 weeks treatment

›
07 November 2011 Hepatitis C: Interferon-free combination of BI 201335 plus BI 207127 and ribavirin shows up to 76% of patients achieve ...
Wednesday, October 5, 2011

Interferon-Free Regimen Shows Promise for Chronic HCV Infection

›
Interferon-Free Regimen Shows Promise for Chronic HCV Infection In a pha se Ib trial, the combination of a polymerase inhibitor, a pr...
Monday, October 3, 2011

AASLD-protease inhibitor BI 201335 and polymerase inhibitor BI 207127 Interferon Free Combo-New Data to be presented by Boehringer

›
New Data from Boehringer Ingelheim HCV Portfolio to be Presented at AASLD PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. announ...
Saturday, April 2, 2011

Hepatitis C compound BI 201335 moves into Phase III clinical trials

›
Boehringer Ingelheim today announced the study outline for the pivotal Phase III clinical trials designed to evaluate BI 201335, its investi...
Monday, November 8, 2010

AASLD 2010 Summary Of Hepatitis C Oral Inhibitors

›
This entry of new investigational oral inhibitors is only a brief collection of data accumulated from following sites: HCV Advocate , CCO,...